NEW YORK (GenomeWeb) – Exact Sciences announced today that the Centers for Medicare and Medicaid Services (CMS) has issued an updated evidence of coverage notice affirming that Medicare Advantage plans must include coverage of the company's Cologuard colon cancer test every three years without patient coinsurance, copayments, or deductibles.

"The CMS update assures patients and physicians that Cologuard is covered by Medicare Advantage plans without any out-of-pocket costs," Exact Chairman and CEO Kevin Conroy said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.